dacomitinib · Pfizer · NDA 211288
Vizimpro
Earliest generic entry, as listed · earliest of 3 marketed strengths
27 Sep 2032
No marketed reference-listed strength; date taken from all listed strengths.
Blocked by patent: US 7772243.
Listed patents · 1 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 7772243 | substance, product | 27 Sep 2032 |
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 3
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 211288 · 001 · RLD · discontinued | tablet, oral | 15MG | 27 Sep 2032 |
| 211288 · 002 · RLD · discontinued | tablet, oral | 30MG | 27 Sep 2032 |
| 211288 · 003 · RLD · discontinued | tablet, oral | 45MG | 27 Sep 2032 |
Expired or delisted (2)
- US 10596162 · use U-3338 · 2 Feb 2026
- US 10603314 · use U-3337 · 2 Feb 2026